Compile Data Set for Download or QSAR
Report error Found 47 Enz. Inhib. hit(s) with all data for entry = 1488
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326332(US9637493, 8.5 | 3-{4-(5-chloropyridin-3- yl)-6-[(...)
Affinity DataIC50: 1nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326330(US9637493, 8.3 | 4-(5-chloropyridin-3-yl)-6- [(1R ...)
Affinity DataIC50: 1nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326329(3-{4-(5-chloropyridin-3- yl)-6-[fluoro(2- fluoroph...)
Affinity DataIC50: 2nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326328(4-(5-chloropyridin-3-yl)-6- [fluoro(2- fluoropheny...)
Affinity DataIC50: 3nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326332(US9637493, 8.5 | 3-{4-(5-chloropyridin-3- yl)-6-[(...)
Affinity DataIC50: 4.5nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326330(US9637493, 8.3 | 4-(5-chloropyridin-3-yl)-6- [(1R ...)
Affinity DataIC50: 8nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326298(5-[2-amino-4- (trifluoromethyl) benzyl]-4-{[(1R)-1...)
Affinity DataIC50: 11nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326326(3-[4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Affinity DataIC50: 13nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326309(5-(4-bromo-3- fluorobenzyl)-4-{[(1R)- 1- cyclobuty...)
Affinity DataIC50: 15nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326295(4-{[(1R)-1- cyclobutylethyl]amino}- 6-(4-methylpyr...)
Affinity DataIC50: 18nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326306(5-(4-chloro-3- fluorobenzyl)-4-{[(1R)- 1- cyclobut...)
Affinity DataIC50: 21nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326296(4-{[(1R)-1- cyclobutylethyl]amino}- 6-[4-(1- methy...)
Affinity DataIC50: 26nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326324(3-[4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Affinity DataIC50: 35nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326320(3-{4-(5-chloropyridin-3- yl)-7-methyl-5-[(trans-4-...)
Affinity DataIC50: 36nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326291(4-{[(1R)-1- cyclobutylethyl]amino}- 6-(2-methoxy-5...)
Affinity DataIC50: 42nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326325(4-(5-chloropyridin-3-yl)-5- [(trans-4- methylcyclo...)
Affinity DataIC50: 47nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326297(4-{[(1R)-1- cyclobutylethyl]amino}- 7-methyl-6-[4-...)
Affinity DataIC50: 50nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326327(3-[4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Affinity DataIC50: 52nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326322(5-{7-benzyl-4-(5- chloropyridin-3-yl)-5- [(trans-4...)
Affinity DataIC50: 54nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326315(3-{4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Affinity DataIC50: 57nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326287((R)-4-((1- cyclobutylethyl)amino)- 6-(2-fluoro-5- ...)
Affinity DataIC50: 62nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326293(6-(2-chloro-5- methylphenyl)-4-{[(1R)- 1- cyclobut...)
Affinity DataIC50: 63nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326323(4-(5-chloropyridin-3-yl)-5- [(trans-4- methylcyclo...)
Affinity DataIC50: 71nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326321(4-(5-chloropyridin-3-yl)-5- [(trans-4- methylcyclo...)
Affinity DataIC50: 72nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326304(4-{[(1R)-1- cyclobutylethyl] amino}-5-[3-fluoro-4-...)
Affinity DataIC50: 87nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326319(4-(5-chloropyridin-3-yl)-7- methyl-5-[(trans-4- me...)
Affinity DataIC50: 88nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326316(5-{4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Affinity DataIC50: 95nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326292(6-(1-benzofuran-5-yl)- 4-{[(1R)-1- cyclobutylethyl...)
Affinity DataIC50: 105nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326318(3-{4-(3-chlorophenyl)-7- methyl-5-[(trans-4- methy...)
Affinity DataIC50: 107nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326311(4-{[(1R)-1- cyclobutylethyl]amino}- 5-(3-fluoro-4-...)
Affinity DataIC50: 124nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326310(4-{[(1R)-1- cyclobutylethyl]amino}- 5-(3,4-difluor...)
Affinity DataIC50: 126nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326290((R)-4-((1- cyclobutylethyl)amino)- 7-methyl-6-(m-t...)
Affinity DataIC50: 130nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326313(3-{4-(3-chlorophenyl)-5- [(trans-4- methylcyclohex...)
Affinity DataIC50: 132nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326289((R)-4-((1- cyclobutylethyl) amino)- 6-(m-tolyl)-5-...)
Affinity DataIC50: 140nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326308(4-{[(1R)-1- cyclobutylethyl]amino}- 6-(3-methylphe...)
Affinity DataIC50: 178nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326317(4-(3-chlorophenyl)-7- methyl-5-[(trans-4- methylcy...)
Affinity DataIC50: 226nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326314(4-(5-chloropyridin-3-yl)-5- [(trans-4- methylcyclo...)
Affinity DataIC50: 247nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326301(4-{[(1R)-1- cyclobutylethyl] amino}-5-[3-fluoro-4-...)
Affinity DataIC50: 267nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326312(4-(3-chlorophenyl)-5- [(trans-4- methylcyclohexyl)...)
Affinity DataIC50: 294nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326300(4-{[(1R)-1- cyclobutylethyl] amino}-6-(3- methylph...)
Affinity DataIC50: 348nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326288((R)-4-((1- cyclobutylethyl)amino)- 7-(2-fluoro-5- ...)
Affinity DataIC50: 353nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326307(4-{[(1R)-1- cyclobutylethyl]amino}- 5-[4- (difluor...)
Affinity DataIC50: 530nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326294(7-(2-chloro-5- methylphenyl)-4-{[(1R)- 1- cyclobut...)
Affinity DataIC50: 712nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326299(4-{[(1R)-1- cyclobutylethyl] amino}-6-(3- methylph...)
Affinity DataIC50: 844nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326303(4-{[(1R)-1- cyclobutylethyl] amino}-5-[4- (difluor...)
Affinity DataIC50: 1.78E+3nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326302(4-{[(1R)-1- cyclobutylethyl]amino}- 5-[2-methoxy-4...)
Affinity DataIC50: 4.37E+3nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM326305(4-{[(1R)-1- cyclobutylethyl] amino}-5-(4- methoxyb...)
Affinity DataIC50: 6.19E+3nMAssay Description:Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
Go to US Patent